Member Area

Farmavita.Net - Pharmaceutical Licensing Network

Friday
Mar 12th
Home arrow Farmavita.Net Journal arrow Business News
Farmavita.Net - Pharmaceutical Business
Print E-mail
Open Innovation
Written by Dwayne H. Spradlin   
Sunday, 12 April 2009

Open innovation network

The Smart Money is on 6 Billion People solving the Problems that Matter

For me, “Open” Innovation embodies the notion that here in the new economy, marketplaces are emerging for ideas that will fundamentally challenge the conventional thinking in areas that include ideation, research, product development, collaboration, and even intellectual property.

Read more...
 
Print E-mail
Press Release
Written by Datamonitor   
Thursday, 09 April 2009

datamonitor_logo.gifAfinitor boasts considerable commercial potential

The FDA has approved Novartis's Afinitor for advanced renal cell carcinoma patients who have progressed after first-line Sutent or Nexavar treatment. Not only is this Afinitor's first approval in the oncology market, the commercial potential in this indication is considerable as there are currently no approved second-line therapy options.

Read more...
 
Print E-mail
Press Release
Written by Datamonitor   
Friday, 03 April 2009

datamonitor_logo.gif

High unmet needs remain for TB in the developing world

Despite being a global disease, the burden of tuberculosis is most severe in developing countries, particularly Asia and Africa. In these regions, case detection rates are low, which poses a significant obstacle for its control. Although the key unmet need in the developing world is a novel vaccine targeting the pulmonary instance of the disease, new antibiotics may hold significant potential.

Read more...
 
Print E-mail
Press Release
Written by Datamonitor   
Friday, 27 March 2009

datamonitor_logo.gif

Telehealth holds great potential but wider awareness may not lead to adoption

Datamonitor believes that telehealth has reached the tipping point in terms of awareness, with IBM following Intel's entrance into the market, prominent media coverage and a rise in the number of conferences highlighting the technology. However, despite the benefits that telehealth offers to both providers and patients, the question remains as to whether this awareness will lead to adoption.

Read more...
 
Print E-mail
Press Release
Wednesday, 25 March 2009
hemcon-logo-hr.jpg

 

 

HemCon Medical Technologies, Inc. Announces Improved, Results from Live Nail Infection Study 

Testing Continues to Validate Breakthrough Anti-Fungal Nail Treatment  

PORTLAND, Ore. – March 25, 2009 – HemCon today announced results from an independent study investigating the time required to successfully treat fungal infected human nails which is a leading cause of Onychomycosis, the most common type of fungal nail infection.

Read more...
 
Print E-mail
Press Release
Written by Datamonitor   
Friday, 20 March 2009

datamonitor_logo.gif

Biosimilars: time for an approval pathway in the US

Congress has received another bill seeking to establish a biosimilars approval pathway in the US.

HR 1427 represents the latest attempt to secure legislation for a biosimilars approval pathway in the US. With a five year exclusivity period, the proposed bill will be viewed as pro-biosimilar and could therefore face considerable opposition from prescription drug manufacturers. However, given the escalating cost of healthcare in the US, the industry is under pressure to find a solution.

Read more...
 
Print E-mail
Press Release
Written by Datamonitor   
Friday, 13 March 2009

datamonitor_logo.gifMerck and Schering-Plough mega-merger to create a company greater than the sum of its parts

As a standalone company, Merck & Co. faces a tough future of declining sales. Datamonitor forecasts that the merger with Schering-Plough will succeed in returning Merck to positive sales growth and provide a raft of new pipeline and marketed products. However, before this can be achieved, outstanding issues surrounding Schering-Plough's partnership with Johnson & Johnson must be resolved.

Read more...
 
Print E-mail
Press Release
Written by Datamonitor   
Friday, 06 March 2009

datamonitor_logo.gifBiosimilars in the EU: delivering the goods?

In January, leading pharmaceutical experts attended the 2009 Forum Institute seminar on biosimilars, and the challenges involved in their successful development and launch. While the main focus of the meeting the biosimilars market in the EU, it was widely agreed that developments in the US, and President Obama's handling of the generic biotech issue, will be the defining issue of 2009 and beyond.

Read more...
 
Print E-mail
Open Innovation
Written by Dr. Paul Stoffels   
Wednesday, 04 March 2009

The Boston Globe Logo

by Dr. Paul Stoffels, the company group chairman of pharmaceutical research and development at Johnson & Johnson

Collaborative innovation for the post-crisis world

LAST WEEK, world and business leaders converged at Davos to wrestle with the global economic crisis and discuss solutions for "Shaping the Post-Crisis World" in six areas, including economics, politics, innovation, science, technology, and new business models. As a physician, a pharmaceutical research and development business leader, and a global citizen, I see one major road to economic recovery and that is through innovation.

Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Results 46 - 54 of 95
Advertisement

Featured Video

More videos ...

3D Content Cloud

Featured Partners

farmavita_research-store.gif
top-20-cancer-therapy-brand.jpg
generics-growth-strategies2.gif
sfe_eu10_150x150_v2.gif 
mddexeceu10_150x150_v1.gif
discovery2010_150x150.gif
150x150_salesonco-master.gif
pharma_omaeu10_150x150_v2.gif
risksharingnextlevel.gif 
arriello-150x150.gif 
150x150_ceepr3_master.gif 
pharmabrand2010_150x150.gif
 

Login to Farmavita.Net

membership is FREE

Follow us on:

bpe_oglas.gif




Join our LinkedIn Group

BabelFish Translator




Click Flag for Translation

Who's Online

We have 7 guests online

Farmavita.Net RSS News


Products

Click to Products

JobLine

Click here ...Post a Job for Free

Reports

Click to Reports

Events

Click to Events

CRAMS

Click to CRAMS